Raymond James analyst Dane Leone reiterated a Hold rating on Denali Therapeutics (DNLI) yesterday. The company’s shares closed last Tuesday at $55.33.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 15.1% and a 62.0% success rate. Leone covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Adverum Biotechnologies, and Tarsus Pharmaceuticals.
Currently, the analyst consensus on Denali Therapeutics is a Moderate Buy with an average price target of $87.80, representing a 52.6% upside. In a report issued on May 2, BTIG also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $93.94 and a one-year low of $21.41. Currently, Denali Therapeutics has an average volume of 535.5K.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNLI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.